{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T06:49:28Z","timestamp":1785912568938,"version":"3.56.0"},"reference-count":78,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Clinics of North America"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.ucl.2026.03.007","type":"journal-article","created":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T21:51:54Z","timestamp":1777499514000},"page":"429-440","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Molecular and Genetic Insights for Personalized Treatment of Non-Muscle-Invasive Bladder Cancer"],"prefix":"10.1016","volume":"53","author":[{"given":"Jose I.","family":"Nolazco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kendrick","family":"Yim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keyan","family":"Salari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ucl.2026.03.007_bib1","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-22465-w","article-title":"An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancer","volume":"12","author":"Lindskrog","year":"2021","journal-title":"Nat Commun"},{"issue":"5","key":"10.1016\/j.ucl.2026.03.007_bib2","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.eururo.2024.12.002","article-title":"The financial burden of localized and metastatic bladder cancer","volume":"87","author":"Scilipoti","year":"2025","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.ucl.2026.03.007_bib3","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.eururo.2024.07.027","article-title":"European association of urology guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in Situ)-A summary of the 2024 guidelines update","volume":"86","author":"Gontero","year":"2024","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.ucl.2026.03.007_bib4","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/s41588-024-02030-z","article-title":"Comprehensive genomic characterization of early-stage bladder cancer","volume":"57","author":"Prip","year":"2025","journal-title":"Nat Genet"},{"issue":"1","key":"10.1016\/j.ucl.2026.03.007_bib5","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1007\/s12672-025-02128-8","article-title":"Review of recent molecular pathology of bladder urothelial carcinoma","volume":"16","author":"Su","year":"2025","journal-title":"Discov Oncol"},{"issue":"3","key":"10.1016\/j.ucl.2026.03.007_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.eururo.2005.12.031","article-title":"Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials","volume":"49","author":"Sylvester","year":"2006","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.ucl.2026.03.007_bib7","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1016\/j.juro.2009.07.016","article-title":"Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus calmette-guerin: the CUETO scoring model","volume":"182","author":"Fernandez-Gomez","year":"2009","journal-title":"J Urol"},{"issue":"4","key":"10.1016\/j.ucl.2026.03.007_bib8","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.eururo.2020.12.033","article-title":"European association of urology (EAU) prognostic factor risk groups for non-muscle-invasive bladder cancer (NMIBC) incorporating the WHO 2004\/2016 and WHO 1973 classification systems for grade: an update from the EAU NMIBC guidelines panel","volume":"79","author":"Sylvester","year":"2021","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.ucl.2026.03.007_bib9","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","article-title":"European Association of Urology Guidelines on non-muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ)","volume":"81","author":"Babjuk","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.ucl.2026.03.007_bib10","doi-asserted-by":"crossref","DOI":"10.37349\/etat.2025.1002301","article-title":"Bladder cancer biomarkers","volume":"6","author":"Godlewski","year":"2025","journal-title":"Explor Target Antitumor Ther"},{"key":"10.1016\/j.ucl.2026.03.007_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2023.102530","article-title":"Role of FGFR3 in bladder cancer: treatment landscape and future challenges","volume":"115","author":"Ascione","year":"2023","journal-title":"Cancer Treat Rev"},{"issue":"2","key":"10.1016\/j.ucl.2026.03.007_bib12","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.eururo.2024.09.012","article-title":"FGFR inhibition in urothelial carcinoma","volume":"87","author":"Li","year":"2025","journal-title":"Eur Urol"},{"issue":"9","key":"10.1016\/j.ucl.2026.03.007_bib13","doi-asserted-by":"crossref","first-page":"7867","DOI":"10.1007\/s11033-023-08689-7","article-title":"Molecular classification of urothelial bladder carcinoma","volume":"50","author":"Schwarzova","year":"2023","journal-title":"Mol Biol Rep"},{"issue":"9","key":"10.1016\/j.ucl.2026.03.007_bib14","doi-asserted-by":"crossref","DOI":"10.1002\/gcc.23271","article-title":"17p13 (TP53) deletions are associated with an aggressive phenotype but unrelated to patient prognosis in urothelial bladder carcinomas","volume":"63","author":"Kluth","year":"2024","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.ucl.2026.03.007_bib15","article-title":"Comparative analysis of differentially mutated genes in non-muscle and muscle-invasive bladder cancer in the Chinese population by whole exome sequencing","volume":"13","author":"Wang","year":"2022","journal-title":"Front Genet"},{"issue":"12","key":"10.1016\/j.ucl.2026.03.007_bib16","article-title":"Stage-stratified molecular profiling of non-muscle-invasive bladder cancer enhances biological, clinical, and therapeutic insight","volume":"2","author":"Hurst","year":"2021","journal-title":"Cell Rep Med"},{"issue":"3","key":"10.1016\/j.ucl.2026.03.007_bib17","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1007\/s11912-025-01645-7","article-title":"Advancements in the diagnosis, treatment, and risk stratification of non-muscle invasive bladder cancer","volume":"27","author":"Smani","year":"2025","journal-title":"Curr Oncol Rep"},{"issue":"33","key":"10.1016\/j.ucl.2026.03.007_bib18","doi-asserted-by":"crossref","first-page":"5218","DOI":"10.1038\/sj.onc.1208705","article-title":"FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma","volume":"24","author":"Jebar","year":"2005","journal-title":"Oncogene"},{"issue":"2","key":"10.1016\/j.ucl.2026.03.007_bib19","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41568-020-00313-1","article-title":"Advances in bladder cancer biology and therapy","volume":"21","author":"Tran","year":"2021","journal-title":"Nat Rev Cancer"},{"issue":"9","key":"10.1016\/j.ucl.2026.03.007_bib20","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1038\/ng.907","article-title":"Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder","volume":"43","author":"Gui","year":"2011","journal-title":"Nat Genet"},{"key":"10.1016\/j.ucl.2026.03.007_bib21","article-title":"Promoter mutations and methylation for telomerase activation in urothelial carcinomas: new mechanistic insights and clinical significance","volume":"13","author":"Liu","year":"2022","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.ucl.2026.03.007_bib22","doi-asserted-by":"crossref","DOI":"10.1002\/2056-4538.70012","article-title":"Loss of MTAP expression is strongly linked to homozygous 9p21 deletion, unfavorable tumor phenotype, and noninflamed microenvironment in urothelial bladder cancer","volume":"11","author":"Gorbokon","year":"2025","journal-title":"J Pathol Clin Res"},{"issue":"1","key":"10.1016\/j.ucl.2026.03.007_bib23","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s12920-019-0579-3","article-title":"Integrative genomic analyses of APOBEC-mutational signature, expression and germline deletion of APOBEC3 genes, and immunogenicity in multiple cancer types","volume":"12","author":"Chen","year":"2019","journal-title":"BMC Med Genom"},{"issue":"4","key":"10.1016\/j.ucl.2026.03.007_bib24","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.urolonc.2012.04.002","article-title":"Combining molecular and pathologic data to prognosticate non-muscle-invasive bladder cancer","volume":"30","author":"van Rhijn","year":"2012","journal-title":"Urol Oncol"},{"issue":"11","key":"10.1016\/j.ucl.2026.03.007_bib25","doi-asserted-by":"crossref","first-page":"926","DOI":"10.3390\/cells13110926","article-title":"Distinct infiltration of T cell populations in bladder cancer molecular subtypes","volume":"13","author":"Sincic","year":"2024","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.ucl.2026.03.007_bib26","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1038\/s41598-020-58351-6","article-title":"Evaluation of PD-L1 and other immune markers in bladder urothelial carcinoma stratified by histologic variants and molecular subtypes","volume":"10","author":"Li","year":"2020","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.ucl.2026.03.007_bib27","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.annonc.2023.09.3116","article-title":"Erdafitinib in BCG-treated high-risk non-muscle-invasive bladder cancer","volume":"35","author":"Catto","year":"2024","journal-title":"Ann Oncol"},{"issue":"697","key":"10.1016\/j.ucl.2026.03.007_bib28","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abn4118","article-title":"Non-muscle-invasive bladder cancer molecular subtypes predict differential response to intravesical bacillus calmette-gu\u00e9rin","volume":"15","author":"de Jong","year":"2023","journal-title":"Sci Transl Med"},{"issue":"4","key":"10.1016\/j.ucl.2026.03.007_bib29","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s00428-019-02593-x","article-title":"Predicting outcomes in non-muscle invasive (Ta\/T1) bladder cancer: the role of molecular grade based on luminal\/basal phenotype","volume":"475","author":"Rebola","year":"2019","journal-title":"Virchows Arch"},{"issue":"3","key":"10.1016\/j.ucl.2026.03.007_bib30","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.eururo.2017.05.040","article-title":"Prognostic impact of a 12-gene progression score in non-muscle-invasive bladder cancer: a prospective multicentre validation study","volume":"72","author":"Dyrskj\u00f8t","year":"2017","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.ucl.2026.03.007_bib31","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1186\/s12885-025-14273-y","article-title":"Novel gene expression-based risk stratification tool predicts recurrence in Non-muscle invasive bladder cancer","volume":"25","author":"N","year":"2025","journal-title":"BMC Cancer"},{"issue":"3","key":"10.1016\/j.ucl.2026.03.007_bib32","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.eururo.2017.03.010","article-title":"Genetic alterations in the molecular subtypes of bladder cancer: illustration in the cancer genome atlas dataset","volume":"72","author":"Choi","year":"2017","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.ucl.2026.03.007_bib33","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/s41585-025-01075-x","article-title":"HER2 and urothelial carcinoma: current understanding and future directions","volume":"23","author":"Raggi","year":"2026","journal-title":"Nat Rev Urol"},{"issue":"1","key":"10.1016\/j.ucl.2026.03.007_bib34","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/path.6367","article-title":"Proteomic analysis of non-muscle invasive and muscle invasive bladder cancer highlights distinct subgroups with metabolic, matrisomal, and immune hallmarks and emphasizes importance of the stromal compartment","volume":"265","author":"Dinh","year":"2025","journal-title":"J Pathol"},{"issue":"2","key":"10.1016\/j.ucl.2026.03.007_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2021.06.021","article-title":"High expression of ERBB2 is an independent risk factor for reduced recurrence-free survival in patients with stage T1 non-muscle-invasive bladder cancer","volume":"40","author":"Sikic","year":"2022","journal-title":"Urol Oncol"},{"issue":"19","key":"10.1016\/j.ucl.2026.03.007_bib36","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14194570","article-title":"Addition of chromosome 17 polysomy and amplification status improves the accuracy of clinicopathological factor-based progression risk stratification and tumor grading of non-muscle-invasive bladder cancer","volume":"14","author":"Kocsm\u00e1r","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ucl.2026.03.007_bib37","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1301510","article-title":"HER2 positivity predicts BCG unresponsiveness and adaptive immune cell exhaustion in EORTC risk-stratified cohort of bladder cancer","volume":"14","author":"Nam","year":"2023","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.ucl.2026.03.007_bib38","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1007\/s12672-025-02751-5","article-title":"HER2 prognostic values in non-muscle-invasive bladder cancer: a step towards personalized treatment for BCG instillation","volume":"16","author":"Deng","year":"2025","journal-title":"Discov Oncol"},{"issue":"1","key":"10.1016\/j.ucl.2026.03.007_bib39","article-title":"Tumor microenvironment heterogeneity in bladder cancer identifies biologically distinct subtypes predicting prognosis and anti-PD-L1 responses","volume":"13","author":"Li","year":"2023","journal-title":"Sci Rep"},{"issue":"12","key":"10.1016\/j.ucl.2026.03.007_bib40","doi-asserted-by":"crossref","first-page":"3963","DOI":"10.1111\/cas.16333","article-title":"Tumor immune microenvironment dynamics and outcomes of prognosis in non-muscle-invasive bladder cancer","volume":"115","author":"Kamitani","year":"2024","journal-title":"Cancer Sci"},{"issue":"1","key":"10.1016\/j.ucl.2026.03.007_bib41","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/s41392-024-01979-x","article-title":"Cold and hot tumors: from molecular mechanisms to targeted therapy","volume":"9","author":"Wu","year":"2024","journal-title":"Signal Transduct Targeted Ther"},{"issue":"1","key":"10.1016\/j.ucl.2026.03.007_bib42","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s00345-024-05392-5","article-title":"PD-L1 expression in high-risk non-muscle invasive bladder cancer is not a biomarker of response to BCG","volume":"43","author":"de Jong","year":"2025","journal-title":"World J Urol"},{"issue":"6","key":"10.1016\/j.ucl.2026.03.007_bib43","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.eururo.2022.09.008","article-title":"Elevated T-cell exhaustion and urinary tumor DNA levels are associated with bacillus calmette-Gu\u00e9rin failure in patients with non\u2013muscle-invasive bladder cancer","volume":"82","author":"Strandgaard","year":"2022","journal-title":"Eur Urol"},{"issue":"8","key":"10.1016\/j.ucl.2026.03.007_bib44","article-title":"Integrating the PD-L1 prognostic biomarker in non-muscle invasive bladder cancer in clinical practice-A comprehensive review on state-of-the-art advances and critical issues","volume":"13","author":"Sanguedolce","year":"2024","journal-title":"J Clin Med [Internet]"},{"issue":"6","key":"10.1016\/j.ucl.2026.03.007_bib45","doi-asserted-by":"crossref","first-page":"391.e1","DOI":"10.1016\/j.urolonc.2025.01.015","article-title":"Impact of baseline PD-L1 status in BCG naive nonmuscle invasive bladder cancer on outcomes and changes after BCG exposure","volume":"43","author":"Gerald","year":"2025","journal-title":"Urol Oncol"},{"key":"10.1016\/j.ucl.2026.03.007_bib46","article-title":"Tumor microenvironment and epithelial-mesenchymal transition in bladder cancer: cytokines in the game?","volume":"9","author":"Martins-Lima","year":"2022","journal-title":"Front Mol Biosci"},{"key":"10.1016\/j.ucl.2026.03.007_bib47","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1146\/annurev-pathmechdis-051222-122423","article-title":"Update on epithelial-mesenchymal plasticity in cancer progression","volume":"19","author":"Fontana","year":"2024","journal-title":"Annu Rev Pathol"},{"issue":"22","key":"10.1016\/j.ucl.2026.03.007_bib48","article-title":"Utility of a molecular signature for predicting recurrence and progression in non-muscle-invasive bladder cancer patients: Comparison with the EORTC, CUETO and 2021 EAU risk groups","volume":"23","author":"Piao","year":"2022","journal-title":"Int J Mol Sci [Internet]"},{"issue":"2","key":"10.1016\/j.ucl.2026.03.007_bib49","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41585-024-00914-7","article-title":"Molecular biomarkers of progression in non-muscle-invasive bladder cancer - beyond conventional risk stratification","volume":"22","author":"Olislagers","year":"2025","journal-title":"Nat Rev Urol"},{"issue":"18","key":"10.1016\/j.ucl.2026.03.007_bib50","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1001\/jama.2018.4657","article-title":"Effect of intravesical instillation of gemcitabine vs saline immediately following resection of suspected low-grade non-muscle-invasive bladder cancer on tumor recurrence: SWOG S0337 randomized clinical trial","volume":"319","author":"Messing","year":"2018","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.ucl.2026.03.007_bib51","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.3050","article-title":"Management, surveillance patterns, and costs associated with low-grade papillary stage Ta non-muscle-invasive bladder cancer among older adults, 2004-2013","volume":"5","author":"Bree","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"2","key":"10.1016\/j.ucl.2026.03.007_bib52","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s00345-022-04253-3","article-title":"Urinary biomarkers for bladder cancer diagnosis and NMIBC follow-up: a systematic review","volume":"41","author":"Soorojebally","year":"2023","journal-title":"World J Urol"},{"issue":"6","key":"10.1016\/j.ucl.2026.03.007_bib53","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.euo.2024.06.005","article-title":"The role of mitomycin C in intermediate-risk non-muscle-invasive bladder cancer: a systematic review and meta-analysis","volume":"7","author":"Scilipoti","year":"2024","journal-title":"Eur Urol Oncol"},{"issue":"4","key":"10.1016\/j.ucl.2026.03.007_bib54","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1111\/bju.16371","article-title":"Adjuvant intravesical therapy in intermediate-risk non-muscle-invasive bladder cancer","volume":"134","author":"Laukhtina","year":"2024","journal-title":"BJU Int"},{"key":"10.1016\/j.ucl.2026.03.007_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2025.104862","article-title":"Emerging biomarkers in bladder cancer: translating molecular advances into precision oncology","volume":"215","author":"Ferro","year":"2025","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.ucl.2026.03.007_bib56","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1394451","article-title":"Comparative efficacy of bacillus calmette-gu\u00e9rin instillation and radical cystectomy treatments for high-risk non-muscle-invasive urothelial cancer classified as high-grade T1 in initial and repeat transurethral resection of bladder tumor","volume":"14","author":"Zhen","year":"2024","journal-title":"Front Oncol"},{"issue":"2","key":"10.1016\/j.ucl.2026.03.007_bib57","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/bju.16509","article-title":"Long-term outcomes of bladder-sparing therapy vs radical cystectomy in BCG-unresponsive non-muscle-invasive bladder cancer","volume":"135","author":"Taylor","year":"2025","journal-title":"BJU Int"},{"issue":"6","key":"10.1016\/j.ucl.2026.03.007_bib58","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1097\/MOU.0000000000001213","article-title":"Does radical cystectomy still have a role in BCG-unresponsive nonmuscle invasive bladder cancer?","volume":"34","author":"Xia","year":"2024","journal-title":"Curr Opin Urol"},{"issue":"3","key":"10.1016\/j.ucl.2026.03.007_bib59","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/bju.13760","article-title":"Guideline of guidelines: non-muscle-invasive bladder cancer","volume":"119","author":"Woldu","year":"2017","journal-title":"BJU Int"},{"issue":"23","key":"10.1016\/j.ucl.2026.03.007_bib60","doi-asserted-by":"crossref","first-page":"5374","DOI":"10.1158\/1078-0432.CCR-24-2015","article-title":"Characterization of FGFR alterations and activation in patients with high-risk non-muscle-invasive bladder cancer","volume":"30","author":"Eisner","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.ucl.2026.03.007_bib61","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.70288","article-title":"Intravesical disitamab vedotin (RC48) for HER2-Expressing high-risk non-muscle-invasive bladder cancer: a single-arm, dose-escalation phase I trial study","volume":"6","author":"Chen","year":"2025","journal-title":"MedComm"},{"issue":"1","key":"10.1016\/j.ucl.2026.03.007_bib62","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S1470-2045(20)30540-4","article-title":"Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial","volume":"22","author":"Boorjian","year":"2021","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.ucl.2026.03.007_bib63","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1158\/1078-0432.CCR-24-2812","article-title":"FDA approval summary: nadofaragene firadenovec-vncg for bacillus calmette-gu\u00e9rin-unresponsive non-muscle-invasive bladder cancer","volume":"31","author":"Colbert","year":"2025","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.ucl.2026.03.007_bib64","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S1470-2045(21)00147-9","article-title":"Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study","volume":"22","author":"Balar","year":"2021","journal-title":"Lancet Oncol"},{"issue":"13","key":"10.1016\/j.ucl.2026.03.007_bib65","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.35966","article-title":"The current and future role of systemic therapy in non-muscle-invasive bladder cancer","volume":"131","author":"Lazarovich","year":"2025","journal-title":"Cancer"},{"issue":"10516","key":"10.1016\/j.ucl.2026.03.007_bib66","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1016\/S0140-6736(25)01897-5","article-title":"Durvalumab in combination with BCG for BCG-naive, high-risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trial","volume":"406","author":"De Santis","year":"2025","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.ucl.2026.03.007_bib67","doi-asserted-by":"crossref","first-page":"507","DOI":"10.2217\/fon-2019-0817","article-title":"KEYNOTE-676: phase III study of BCG and pembrolizumab for persistent\/recurrent high-risk NMIBC","volume":"16","author":"Kamat","year":"2020","journal-title":"Future Oncol"},{"issue":"5","key":"10.1016\/j.ucl.2026.03.007_bib68","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1097\/MOU.0000000000000078","article-title":"The burden of bladder cancer care: direct and indirect costs","volume":"24","author":"Mossanen","year":"2014","journal-title":"Curr Opin Urol"},{"issue":"4","key":"10.1016\/j.ucl.2026.03.007_bib69","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1177\/23523735241304348","article-title":"North American study and meta-analysis evaluating performance of Bladder EpiCheck, a FDA cleared test, in non-muscle invasive bladder cancer recurrence","volume":"10","author":"Fleshner","year":"2024","journal-title":"Bladder Cancer"},{"key":"10.1016\/j.ucl.2026.03.007_bib70","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.3389\/fgene.2019.01237","article-title":"Validation of a novel, sensitive, and specific urine-based test for recurrence surveillance of patients with non-muscle-invasive bladder cancer in a comprehensive multicenter study","volume":"10","author":"Batista","year":"2019","journal-title":"Front Genet"},{"issue":"3","key":"10.1016\/j.ucl.2026.03.007_bib71","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1097\/JU.0000000000004335","article-title":"Uromonitor: clinical validation and performance assessment of a urinary biomarker within the surveillance of patients with nonmuscle-invasive bladder cancer","volume":"213","author":"Ramos","year":"2025","journal-title":"J Urol"},{"issue":"18","key":"10.1016\/j.ucl.2026.03.007_bib72","doi-asserted-by":"crossref","first-page":"3668","DOI":"10.1158\/1078-0432.CCR-23-0570","article-title":"Development and multicenter case-control validation of urinary comprehensive genomic profiling for urothelial carcinoma diagnosis, surveillance, and risk-prediction","volume":"29","author":"Salari","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.ucl.2026.03.007_bib73","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.euo.2024.09.016","article-title":"Minimal residual disease detection with urine-derived DNA is prognostic for recurrence-free survival in bacillus calmette-gu\u00e9rin-unresponsive non-muscle-invasive bladder cancer treated with nadofaragene firadenovec","volume":"8","author":"Narayan","year":"2025","journal-title":"Eur Urol Oncol"},{"issue":"5","key":"10.1016\/j.ucl.2026.03.007_bib74","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.eururo.2025.03.023","article-title":"Urine tumor DNA to stratify the risk of recurrence in patients treated with atezolizumab for bacillus calmette-gu\u00e9rin-unresponsive non-muscle-invasive bladder cancer","volume":"88","author":"St-Laurent","year":"2025","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.ucl.2026.03.007_bib75","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.eururo.2025.03.018","article-title":"Use of the Xpert bladder cancer monitor urinary biomarker test for guiding cystoscopy in high-grade non-muscle-invasive bladder cancer: results from the randomized controlled DaBlaCa-15 trial","volume":"88","author":"Dreyer","year":"2025","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.ucl.2026.03.007_bib76","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1016\/j.juro.2016.12.010","article-title":"Performance characteristics of a multigene urine biomarker test for monitoring for recurrent urothelial carcinoma in a multicenter study","volume":"197","author":"Kavalieris","year":"2017","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.ucl.2026.03.007_bib77","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-77101-6","article-title":"Precise grading of non-muscle invasive bladder cancer with multi-scale pyramidal CNN","volume":"14","author":"Shalata","year":"2024","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.ucl.2026.03.007_bib78","first-page":"192","article-title":"Predicting response to intravesical bacillus calmette-gu\u00e9rin in high-risk nonmuscle-invasive bladder cancer using an artificial intelligence-powered pathology assay: development and validation in an international 12-Center cohort","volume":"213","author":"Lotan","year":"2025","journal-title":"J Urol"}],"container-title":["Urologic Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094014326000339?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094014326000339?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T06:13:55Z","timestamp":1785910435000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0094014326000339"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":78,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S0094014326000339"],"URL":"https:\/\/doi.org\/10.1016\/j.ucl.2026.03.007","relation":{},"ISSN":["0094-0143"],"issn-type":[{"value":"0094-0143","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular and Genetic Insights for Personalized Treatment of Non-Muscle-Invasive Bladder Cancer","name":"articletitle","label":"Article Title"},{"value":"Urologic Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ucl.2026.03.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}